BOLD BOUNDLESS BIO INC

Boundless Bio to Participate in the Leerink Global Healthcare Conference

Boundless Bio to Participate in the Leerink Global Healthcare Conference

SAN DIEGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in Leerink’s Global Healthcare Conference.

A fireside chat session is scheduled for Wednesday, March 12, 2025, in Miami, FL, at 11:20 a.m. ET. A live and archived webcast of the session will be accessible under “Events & Presentations” in the Investors section of Boundless Bio’s website and can be accessed via this link: .

About Boundless Bio

Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in 14 to 17% of cancer patients. Boundless Bio is developing the first ecDNA-directed therapeutic candidate (ecDTx), BBI-355, which is an oral inhibitor of checkpoint kinase 1 (CHK1) being evaluated in a Phase 1/2 clinical trial in patients with oncogene amplified cancers. Leveraging its Spyglass platform, Boundless Bio has additional programs advancing through preclinical development and discovery. Boundless Bio is headquartered in San Diego, CA. For more information, visit  and follow us on  and .

Contacts:

Ben Flaum, Boundless Bio

Investors

THRUST Strategic Communications

Renee Leck



EN
26/02/2025

Underlying

BOLDBOUNDLESS BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BOUNDLESS BIO INC

 PRESS RELEASE
Free
BOLD BOUNDLESS BIO I...

Boundless Bio to Participate in the Needham Virtual Healthcare Confere...

Boundless Bio to Participate in the Needham Virtual Healthcare Conference SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in Needham’s Virtual Healthcare Conference. A company presentation is scheduled for Thursday, April 10, 2025, at 1:30 p.m. ET. A live and archived webcast of the session will ...

April 3, 2025 1 EN
 PRESS RELEASE
Free
BOLD BOUNDLESS BIO I...

Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Resu...

Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights BBI-355 Phase 1/2 POTENTIATE trial ongoing in patients with oncogene amplified cancers, with initial proof of concept data expected in the second half of 2025 Novel Kinesin program progressing toward development candidate nomination by mid-2025, with IND submission expected in the first half of 2026 With a $152 million cash position at the end of 2024, Boundless projects operating runway into 2027 SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BOLD), a clinical-stage oncology com...

March 27, 2025 1 EN
 PRESS RELEASE
Free
BOLD BOUNDLESS BIO I...

Boundless Bio to Participate in the Leerink Global Healthcare Conferen...

Boundless Bio to Participate in the Leerink Global Healthcare Conference SAN DIEGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in Leerink’s Global Healthcare Conference. A fireside chat session is scheduled for Wednesday, March 12, 2025, in Miami, FL, at 11:20 a.m. ET. A live and archived webcast of the...

February 26, 2025 1 EN
 PRESS RELEASE
Free
BOLD BOUNDLESS BIO I...

Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical O...

Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer - Dr. Doebele has over 15 years of oncology drug development experience as a public company Chief Medical Officer and clinical researcher at leading cancer centers - SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Robert (“Bob”) Doebele, M.D., Ph.D., has been appointed as Chief Medical Offic...

February 3, 2025 1 EN
 PRESS RELEASE
Free
BOLD BOUNDLESS BIO I...

Boundless Bio Announces Pipeline and Leadership Updates

Boundless Bio Announces Pipeline and Leadership Updates Company elects not to advance BBI-825 into Part 2 portion of STARMAP clinical trial Third ecDTx program advancing, with plans for development candidate nomination by mid-2025 Operating runway extended into 2027, through anticipated clinical readout for BBI-355 and key development milestones for third ecDTx program Klaus Wagner, M.D., Ph.D., Chief Medical Officer, and Neil Abdollahian, Chief Business Officer, stepping down; James L. Freddo, M.D., to serve as Interim Chief Medical Officer SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE)...

December 12, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch